Glycine and Magnesium+Thiamine for the Treatment of Primary Ciliary Dyskinesia

Launched by INSTITUTO NACIONAL DE ENFERMEDADES RESPIRATORIAS · May 5, 2025

Keywords

ClinConnect Summary

This clinical trial is exploring whether oral supplements of glycine and magnesium combined with thiamine can help improve lung function and overall well-being in patients with primary ciliary dyskinesia (PCD). PCD is a condition that makes it difficult for patients to clear mucus from their lungs, which can lead to serious lung damage over time. Since there is currently no specific treatment for PCD, this study aims to see if these supplements can reduce symptoms and improve quality of life by helping to clear mucus and reduce inflammation.

To participate, individuals must be at least 5 years old and have a confirmed diagnosis of PCD. They should not have experienced any respiratory problems or infections in the 30 days prior to the trial. Over six months, participants will receive either glycine, magnesium plus thiamine, a combination of both, or a placebo (a harmless powder that looks the same as the other treatments). Researchers will monitor how well these treatments work in reducing disease flare-ups and improving lung function. This study is not yet recruiting participants, but it holds promise for better managing PCD in the future.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Any sex.
• • 2. Age of 5 years or more.
• • 3. Diagnosis of primary ciliary dyskinesia (PCD) established according to international recommendations (Shapiro et al. Am J Respir Crit Care Med 2018;197(12):e24-e39, and Shapiro et al. Ped Pulmonol 2016;51:115-132).
• • 4. Without respiratory exacerbations of PCD in the previous 30 days.
• • 5. Without acute respiratory infection in the previous 30 days.
• • 6. Informed consent letter signed by the patient (if the patient's age is 18 years or more).
• • 7. Informed consent letter signed by the legal guardian, and assent letter signed by the patient (if the patient's age is \<18 years).
• Exclusion Criteria:
• • 1. Participation in other research protocol involving therapeutic measures.
• Elimination Criteria:
• • 1. None.